Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response.
暂无分享,去创建一个
J. Mate | J. Gisbert | J. Mendoza | C. Taxonera | F. Bermejo | J. Pérez-Calle | L. Menchen | I. Marín-Jiménez | M. Calvo | Y. González-Lama | N. López-Palacios | L. Abreu | I. Vera | B. Casís | F. Sánchez | J. Milicua | P. Martínez-Montiel | A. Huerta | A. López-San Román | J. Carneros | P. López | F. Martínez-Silva
[1] M. Gassull,et al. Efficacy and safety of short‐term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open‐label, multicentre trial , 2007, Alimentary pharmacology & therapeutics.
[2] M. Silverberg,et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[3] H. Tilg,et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. , 2010, Journal of Crohn's & colitis.
[4] P. Rutgeerts,et al. Review article: infliximab therapy for inflammatory bowel disease – seven years on , 2006, Alimentary pharmacology & therapeutics.
[5] F. Nestle,et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial , 2005, The Lancet.
[6] J. S. Kim,et al. [Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea]. , 2005, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.
[7] E. Doménech,et al. Recomendaciones GETECCU-2005 para el uso de infliximab (Remicade®) en la enfermedad inflamatoria intestinal , 2005 .
[8] Y. Panis. L’approche combinée médico-chirurgicale (séton + infliximab + azathioprine) : la panacée dans les lesions anopérinéales de Crohn ? , 2005 .
[9] L. Beaugerie,et al. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery , 2005, Gut.
[10] J. Sarles,et al. Efficacy and Tolerance of Infliximab in Children and Adolescents with Crohn’s Disease , 2004, Inflammatory bowel diseases.
[11] B. Sands,et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[12] H. Tilg,et al. Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up , 2004, European journal of gastroenterology & hepatology.
[13] M. Bala,et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[14] P. Rutgeerts,et al. Optimizing anti-TNF treatment in inflammatory bowel disease. , 2004, Gastroenterology.
[15] P. Rutgeerts,et al. Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.
[16] J. Satsangi,et al. An analysis of factors influencing short‐term and sustained response to infliximab treatment for Crohn's disease , 2003, Alimentary pharmacology & therapeutics.
[17] R. Panaccione,et al. Combined Seton Placement, Infliximab Infusion, and Maintenance Immunosuppressives Improve Healing Rate in Fistulizing Anorectal Crohn’s Disease , 2003, Diseases of the colon and rectum.
[18] M. Peppercorn,et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. , 2003, Gastroenterology.
[19] M. Badea,et al. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania. , 2003, Romanian journal of gastroenterology.
[20] An Carbonez,et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.
[21] R. Baldassano,et al. Safety and Steroid-Sparing Experience Using Infliximab for Crohn's Disease at a Pediatric Inflammatory Bowel Disease Center , 2003, American Journal of Gastroenterology.
[22] J. Achkar,et al. Predictors of response to infliximab in patients with Crohn's disease. , 2002, Gastroenterology.
[23] J. Belaiche,et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease , 2002, American Journal of Gastroenterology.
[24] G. Porro,et al. Infliximab in treatment of Crohn's disease: the Milan experience. , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[25] E. Schoon,et al. Effects of anti‐tumour necrosis factor‐α therapy on the quality of life in Crohn's disease , 2002, Alimentary pharmacology & therapeutics.
[26] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[27] J. Mendoza,et al. Infliximab treatment and prognostic factors for response in patients with Crohn's disease. , 2002, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
[28] D. Hommes,et al. Infliximab Treatment for Crohn's Disease: One-Year Experience in a Dutch Academic Hospital , 2002, Inflammatory bowel diseases.
[29] C. Sample,et al. Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta. , 2002, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[30] E. Doménech,et al. Recomendaciones para el uso de infliximab (Remicade®) en la enfermedad de Crohn. GETECCU 2001 , 2002 .
[31] A. Zinsmeister,et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.
[32] R. Cohen. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. , 2001, Inflammatory bowel diseases.
[33] W. Selby,et al. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor‐α, in the treatment of Crohn’s disease: is its efficacy augmented by steroid‐sparing immunosuppressive therapy? , 2001 .
[34] P. Martreau. [A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators]. , 2000, Gastroenterologie clinique et biologique.
[35] G. Greenberg,et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. , 2000, The New England journal of medicine.
[36] W. Sandborn,et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients , 2000, American Journal of Gastroenterology.
[37] M. Kamm,et al. Infliximab for the treatment of fistulas in patients with Crohn'S disease. , 1999, Gastroenterology.
[38] S. V. Deventer,et al. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab. , 1999 .
[39] A. Kornbluth. Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference. , 1998, Inflammatory bowel diseases.
[40] H. Lamb,et al. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. , 1998, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
[41] R. Löfberg,et al. Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. , 1998, Gastroenterology.
[42] B. Feagan. Methotrexate treatment for Crohn's disease. , 1998, Inflammatory bowel diseases.
[43] R. Modigliani,et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine , 1996, The Lancet.
[44] M. Gerig,et al. A controlled double blind study of azathioprine in the management of Crohn's disease. , 1995, Gut.
[45] P. Munkholm,et al. Disease activity courses in a regional cohort of Crohn's disease patients. , 1995, Scandinavian journal of gastroenterology.
[46] Loyd,et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. , 1995, The New England journal of medicine.
[47] P. Munkholm,et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. , 1994, Gut.
[48] B. Pasternack,et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. , 1980, The New England journal of medicine.
[49] J. Panés,et al. [GETECCU-2005 recommendations for the use of infliximab (Remicade) in inflammatory bowel disease]. , 2005, Gastroenterologia y hepatologia.
[50] J. Panés,et al. [Recommendations for the use of infliximab (Remicade) in Crohn's disease. GETECCU 2001]. , 2002, Gastroenterologia y hepatologia.
[51] W. Selby,et al. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. , 2001, Internal medicine journal.